Karyopharm Therapeutics Target of Unusually Large Options Trading (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of some unusual options trading on Thursday. Stock traders acquired 10,965 call options on the stock. This is an increase of 817% compared to the average volume of 1,196 call options.

Karyopharm Therapeutics Stock Down 6.6%

NASDAQ KPTI traded down $0.67 on Thursday, reaching $9.42. 317,017 shares of the stock traded hands, compared to its average volume of 572,696. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $10.99. The firm’s fifty day simple moving average is $7.48 and its 200 day simple moving average is $6.56. The company has a market cap of $172.76 million, a price-to-earnings ratio of -0.57 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The company had revenue of $34.08 million for the quarter, compared to analyst estimates of $33.16 million. As a group, equities research analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Piper Sandler restated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, February 18th. Royal Bank Of Canada decreased their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.83.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its stake in shares of Karyopharm Therapeutics by 112.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after acquiring an additional 790,417 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in Karyopharm Therapeutics in the 4th quarter worth $74,000. Ikarian Capital LLC increased its holdings in shares of Karyopharm Therapeutics by 1,897.9% during the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after purchasing an additional 517,297 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $95,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $439,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.